Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia ... Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.23 | -4.82180293501 | 4.77 | 4.78 | 4.03 | 496589 | 4.22711442 | CS |
| 4 | -0.87 | -16.0813308688 | 5.41 | 5.47 | 4.03 | 697373 | 4.7799962 | CS |
| 12 | -1.25 | -21.5889464594 | 5.79 | 7.015 | 4.03 | 833360 | 5.61661467 | CS |
| 26 | -5.24 | -53.5787321063 | 9.78 | 10.99 | 4.03 | 1000711 | 7.25689313 | CS |
| 52 | 0.09 | 2.02247191011 | 4.45 | 10.99 | 3.6 | 925980 | 7.34571312 | CS |
| 156 | -4.96 | -52.2105263158 | 9.5 | 22.33 | 1.45 | 584985 | 7.24287258 | CS |
| 260 | -4.96 | -52.2105263158 | 9.5 | 22.33 | 1.45 | 584985 | 7.24287258 | CS |
Trades verzögert
Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto
Auf Echtzeit aktualisieren| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
